Median Technologies signs 3-year deal with US Ph I cancer trial centre
The deal will START researchers use Median’s lesion management solutions (LMS) technology to analyse images taken during early phase clinical trials of cancer drugs. The idea, according to the French software firm, is to allow researchers to make no/ no go treatment decisions earlier.
Median CEO Fredrik Brag, explained that: “Our LMS application provides immense value for better assessing oncology patients’ response to therapy in clinical trials. The addition of our LMS applications to START’s current capabilities will bring tremendous combined value to the Phase I setting.
“Having accurate quantitative information from images helps sponsors make the right decisions regarding the pursuit of research on a given molecule, which ultimately benefits patients.” he added.
START has facilities in San Antonio, Texas, and Madrid, Spain, and claims it conducts the world’s largest Phase I medical oncology program, putting more than 400 patients per year into trials.
The START contract follows just a few months after an unnamed top 10 pharmaceutical industry customer adopted the LMS technology in a €230,000 agreement that will see the technology employed at 20 clinical sites in Europe and the US.
